
Quarterly report 2023-Q3
added 11-07-2023
Eargo Revenue 2011-2026 | EAR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.2 M | 32.1 M | 69.2 M | 32.8 M | 23.2 M | 6.62 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69.2 M | 6.62 M | 33.5 M |
Quarterly Revenue Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.27 M | 8.11 M | 11.8 M | - | 7.91 M | 7.25 M | 9.18 M | - | - | 22.9 M | 22 M | - | 18.2 M | 15.9 M | 12.7 M | - | 7.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | 7.25 M | 12.7 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
764 M | $ 11.97 | -1.48 % | $ 1.8 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.37 | 4.18 % | $ 925 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.04 | -0.71 % | $ 324 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.35 | 0.05 % | $ 120 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Inogen
INGN
|
349 M | $ 6.4 | -0.78 % | $ 170 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 63.27 | 0.05 % | $ 3.45 B | ||
|
LENSAR
LNSR
|
53.5 M | $ 5.72 | -5.77 % | $ 65.9 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 87.03 | -0.17 % | $ 112 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.35 | -0.37 % | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.92 | 0.43 % | $ 472 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
225 M | $ 32.58 | 2.61 % | $ 1.5 B | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 225.09 | -0.88 % | $ 15.8 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.54 | -0.25 % | $ 1.13 B | ||
|
Profound Medical Corp.
PROF
|
7.2 M | $ 5.18 | -4.07 % | $ 180 M | ||
|
Quanterix Corporation
QTRX
|
139 M | $ 3.76 | -4.57 % | $ 160 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
64 M | $ 24.65 | 0.65 % | $ 208 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.59 | 1.74 % | $ 7.18 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.67 | -0.53 % | $ 36.5 M | ||
|
Aethlon Medical
AEMD
|
574 K | $ 2.17 | -5.6 % | $ 3.39 M | ||
|
Sensus Healthcare
SRTS
|
27.5 M | $ 3.98 | -3.16 % | $ 65 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 329.33 | -0.98 % | $ 126 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 26.66 | 0.57 % | $ 610 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 11.16 | 7.62 % | $ 1.51 B | ||
|
Myomo
MYO
|
40.9 M | $ 0.71 | 0.04 % | $ 29.7 M | ||
|
IRadimed Corporation
IRMD
|
83.8 M | $ 99.91 | 0.72 % | $ 1.27 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
1.3 M | $ 2.37 | -3.07 % | $ 139 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.85 | 3.08 % | $ 144 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 16.33 | -0.85 % | $ 383 M |